Nuebling, Georg S; Prix, Catharina; Brendel, Matthias; Beyer, Leonie; Wlasich, Elisabeth; Loosli, Sandra V; Barthel, Henryk; Sabri, Osama; Bartenstein, Peter; Vöglein, Jonathan; Danek, Adrian; Rominger, Axel; Edbauer, Dieter; Haass, Christian; Levin, Johannes (2021). Low-degree trisomy 21 mosaicism promotes early-onset Alzheimer disease. Neurobiology of aging, 103, 147.e1-147.e5. Elsevier 10.1016/j.neurobiolaging.2021.02.021
Text
1-s2.0-S0197458021000762-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB) |
Trisomy-21 mosaicism (mT21) with subclinical intellectual development disorder or physical phenotype has very rarely been associated with early-onset cognitive decline. Notably, early-onset Alzheimer's disease (EOAD) patients' family histories frequently suggest genetic causes other than autosomal-dominant APP/PSEN-1/2 mutations. We present an EOAD patient in his late fifties newly diagnosed with low-degree mT21 (13%/21% blood lymphocytes/ectodermal cells). We applied fluorescence in-situ hybridization to confirm a diagnosis of mT21. Multimodal positron-emission-tomography applying 18F-fluodesoxyglucose (metabolism), 18F-florbetaben (amyloid-β deposits) and 18F-PI-2620 (tau-deposits) tracers was used to confirm a diagnosis of EOAD according to the ATN-criteria of AD. Initial PET-studies revealed marked cerebral amyloid-β- and tau-pathology and parietotemporal hypometabolism, confirming EOAD according to the ATN-criteria of AD. A marked cognitive decline was accompanied by an increase in tau pathology in follow-up studies. This is the first case demonstrating that a low-degree APP gene-dose increase suffices to cause EOAD with prominent amyloid-β/tau pathology.
Item Type: |
Journal Article (Further Contribution) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine |
UniBE Contributor: |
Rominger, Axel Oliver |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0197-4580 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Daria Vogelsang |
Date Deposited: |
19 Jan 2022 16:54 |
Last Modified: |
05 Dec 2022 16:02 |
Publisher DOI: |
10.1016/j.neurobiolaging.2021.02.021 |
PubMed ID: |
33789815 |
Uncontrolled Keywords: |
Alzheimer disease Amyloid Neurogenetics PI-2620 Positron emission tomography Tau |
BORIS DOI: |
10.48350/163977 |
URI: |
https://boris.unibe.ch/id/eprint/163977 |